Douglas Hunt
Fortune : 945 350 $ au 31/05/2026
Fortune : 945 350 $ au 31/05/2026
Mr. Douglas Hunt is a Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. Mr. Hunt was previously employed as a VP-Regulatory Affairs & Quality Assurance by ArmaGen, Inc., a Vice President-Global Regulatory Affairs by Baxter Healthcare Corp., and an Executive Director-Therapeutic Area by Amgen, Inc. He received his undergraduate degree from the University of Portsmouth.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC. 0,26 % | 13/04/2026 | 131 848 ( 0,26 % ) | 945 350 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Conseiller Juridique Général | 01/01/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Conseiller Juridique Général | 01/12/2017 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Conseiller Juridique Général | 01/03/2015 |
| AMGEN INC. | Corporate Officer/Principal | 01/07/2008 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Health Technology |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national